| pubmed-article:10969793 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10969793 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:10969793 | lifeskim:mentions | umls-concept:C0555198 | lld:lifeskim |
| pubmed-article:10969793 | lifeskim:mentions | umls-concept:C0524466 | lld:lifeskim |
| pubmed-article:10969793 | lifeskim:mentions | umls-concept:C0935992 | lld:lifeskim |
| pubmed-article:10969793 | lifeskim:mentions | umls-concept:C1148758 | lld:lifeskim |
| pubmed-article:10969793 | pubmed:issue | 16 | lld:pubmed |
| pubmed-article:10969793 | pubmed:dateCreated | 2000-9-14 | lld:pubmed |
| pubmed-article:10969793 | pubmed:abstractText | Malignant gliomas are the most common intracranial tumors and are considered incurable. Therefore, exploration of novel therapeutic modalities is essential. Telomerase is a ribonucleoprotein enzyme that is detected in the vast majority of malignant gliomas but not in normal brain tissues. We, therefore, hypothesized that telomerase inhibition could be a very promising approach for the targeted therapy of malignant gliomas. Thus, 2-5A (5'-phosphorylated 2'-5'-linked oligoadenylate)-linked antisense against human telomerase RNA component (2-5A-anti-hTER) was investigated for its antitumor effect on an intracranial malignant glioma model. 2-5A is a mediator of one pathway of IFN actions by activating RNase L, resulting in RNA degradation. By linking 2-5A to antisense, RNase L degrades the targeted RNA specifically and effectively. Prior to the experiments using intracranial tumor models in nude mice, we modified the in vitro and in vivo treatment modality of 2-5A-anti-hTER using a cationic liposome to enhance the effect of 2-5A-anti-hTER. Here we demonstrate that 2-5A-anti-hTER complexed with a cationic liposome reduced the viability of five malignant glioma cell lines to 20-43% within 4 days but did not influence the viability of cultured astrocytes lacking telomerase. Furthermore, treatment of intracranial malignant gliomas in nude mice with 2-5A-anti-hTER was therapeutically effective compared with the control (P < 0.01). These findings clearly suggest the therapeutic potentiality of 2-5A-anti-hTER as a novel approach for the treatment of intracranial malignant gliomas. | lld:pubmed |
| pubmed-article:10969793 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10969793 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10969793 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10969793 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10969793 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10969793 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10969793 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10969793 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10969793 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10969793 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10969793 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10969793 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10969793 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10969793 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10969793 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10969793 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10969793 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:10969793 | pubmed:issn | 0008-5472 | lld:pubmed |
| pubmed-article:10969793 | pubmed:author | pubmed-author:KondoYY | lld:pubmed |
| pubmed-article:10969793 | pubmed:author | pubmed-author:KondoSS | lld:pubmed |
| pubmed-article:10969793 | pubmed:author | pubmed-author:KogaSS | lld:pubmed |
| pubmed-article:10969793 | pubmed:author | pubmed-author:MukaiSS | lld:pubmed |
| pubmed-article:10969793 | pubmed:author | pubmed-author:BarnaB PBP | lld:pubmed |
| pubmed-article:10969793 | pubmed:author | pubmed-author:KomataTT | lld:pubmed |
| pubmed-article:10969793 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10969793 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:10969793 | pubmed:volume | 60 | lld:pubmed |
| pubmed-article:10969793 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10969793 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10969793 | pubmed:pagination | 4461-7 | lld:pubmed |
| pubmed-article:10969793 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:10969793 | pubmed:meshHeading | pubmed-meshheading:10969793... | lld:pubmed |
| pubmed-article:10969793 | pubmed:meshHeading | pubmed-meshheading:10969793... | lld:pubmed |
| pubmed-article:10969793 | pubmed:meshHeading | pubmed-meshheading:10969793... | lld:pubmed |
| pubmed-article:10969793 | pubmed:meshHeading | pubmed-meshheading:10969793... | lld:pubmed |
| pubmed-article:10969793 | pubmed:meshHeading | pubmed-meshheading:10969793... | lld:pubmed |
| pubmed-article:10969793 | pubmed:meshHeading | pubmed-meshheading:10969793... | lld:pubmed |
| pubmed-article:10969793 | pubmed:meshHeading | pubmed-meshheading:10969793... | lld:pubmed |
| pubmed-article:10969793 | pubmed:meshHeading | pubmed-meshheading:10969793... | lld:pubmed |
| pubmed-article:10969793 | pubmed:meshHeading | pubmed-meshheading:10969793... | lld:pubmed |
| pubmed-article:10969793 | pubmed:meshHeading | pubmed-meshheading:10969793... | lld:pubmed |
| pubmed-article:10969793 | pubmed:meshHeading | pubmed-meshheading:10969793... | lld:pubmed |
| pubmed-article:10969793 | pubmed:meshHeading | pubmed-meshheading:10969793... | lld:pubmed |
| pubmed-article:10969793 | pubmed:meshHeading | pubmed-meshheading:10969793... | lld:pubmed |
| pubmed-article:10969793 | pubmed:meshHeading | pubmed-meshheading:10969793... | lld:pubmed |
| pubmed-article:10969793 | pubmed:meshHeading | pubmed-meshheading:10969793... | lld:pubmed |
| pubmed-article:10969793 | pubmed:meshHeading | pubmed-meshheading:10969793... | lld:pubmed |
| pubmed-article:10969793 | pubmed:meshHeading | pubmed-meshheading:10969793... | lld:pubmed |
| pubmed-article:10969793 | pubmed:meshHeading | pubmed-meshheading:10969793... | lld:pubmed |
| pubmed-article:10969793 | pubmed:meshHeading | pubmed-meshheading:10969793... | lld:pubmed |
| pubmed-article:10969793 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10969793 | pubmed:articleTitle | 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas. | lld:pubmed |
| pubmed-article:10969793 | pubmed:affiliation | Center for Surgery Research, The Cleveland Clinic Foundation, Ohio 44195, USA. | lld:pubmed |
| pubmed-article:10969793 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10969793 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:10969793 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10969793 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10969793 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10969793 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10969793 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10969793 | lld:pubmed |
